A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

To join this study, people generally need to be at least 18 years old. Both men and women can participate. The study is looking for people who have been diagnosed with a type of cancer called cholangiocarcinoma, which is a cancer that starts in the bile ducts of the liver, or other advanced solid tumors.

Because this is a specific type of drug targeting certain pathways, it's likely that a doctor will need to check if your cancer has specific genetic changes (called FGFR2 alterations) that the medicine is designed to target. You would also need to be well enough to take part in the study, which means having good general health and certain organ functions working properly, such as your kidneys and liver, as assessed by the study doctors.

If you decide to join this study, you would be taking the new medicine, RLY-4008, as directed by the study team. You would have regular visits to the hospital or clinic, which would involve different checks and tests. These might include blood tests, scans (like CT or MRI) to see how your cancer is responding, and assessments of your general health and any side effects you might be experiencing.

These visits would be frequent at the beginning of the study, and then might become less often if you continue to do well on the treatment. The study doctors and nurses would carefully explain the schedule and what to expect at each visit. The total length of your participation would depend on how your body responds to the treatment and how you are feeling, potentially continuing as long as the medicine is helping and you are tolerating it well.